NYSE · RVTY · Diagnostics & Research
Revvity, Inc. (RVTY) stock analysis
- RVTY gained 9.3% over the past month versus 0.0% for the S&P 500, ranking 70th of 497 S&P 500 stocks.
- Over 12 months it returned +64.5%, 48.7 points ahead of the S&P 500, and trades 0.5% below its 52-week high.
- In the last 30 days 1 analyst raised earnings estimates and 1 cut; forward EPS moved +0.1% (+1.2% over 90 days).
- It sits in the Laboratory & analytical tools segment of the Medtech, Diagnostics & Care, where the 1-month median return is +6.4%.
- The daily chart reads Intermediate uptrend · High consolidation (since Oct 21, 2026).
One-year price with 50- and 200-day averages
Performance vs the market
Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.
Chart structure
Read by our daily-bar structure engine from swing highs, swing lows and moving averages.
Holding since Oct 21, 2026
- Close above EMA20 above EMA50
- EMA50 rose over the last ten sessions
- Some swings conflict with the averages
34 occurrences in 10 years. The median move over the next 20 sessions was +0.7%, positive 56% of the time, against +1.5% for any day in the same period.
Analyst earnings revisions
Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.
15 analysts cover the stock
Fundamental shape vs peers
Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.
Ahead of peersMomentum, Valuation
Behind peersGrowth, Profit
PeersTMO · DHR · NTRA · A
Where it sits in the supply chain
Medtech, Diagnostics & Care · Tools & research
Instruments and reagents serve research and labs; budgets and inventories affect orders.
Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps
Risk profile
Track this stock every day
Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.